- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Valion Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Valion Bio: Wirkstoffkandidat Entolimod startet Studie zur therapeutischen Wirksamkeit | 1 | Investing.com Deutsch | ||
| Fr | Valion Bio, Inc.: Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results | 358 | ACCESS Newswire | NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome ("GI-ARS"), after the announcement of positive safety findingsFully funded study will evaluate Entolimod's... ► Artikel lesen | |
| VALION BIO Aktie jetzt für 0€ handeln | |||||
| 28.10. | Valion Bio, Inc.: Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation | 390 | ACCESS Newswire | AFRRI study found no evidence of treatment-related toxicity following a single dose of Entolimod, supporting advancement toward a planned, fully funded therapeutic study evaluating survival and gastrointestinal... ► Artikel lesen | |
| 26.10. | Valion Bio receives unsolicited bids for CDMO subsidiary | 2 | Investing.com | ||
| 26.10. | Valion Bio, Inc.: Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options | 277 | ACCESS Newswire | Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod SAN ANTONIO, TX / ACCESS Newswire / October 26, 2026 / Valion Bio, Inc. (NASDAQ:VBIO)... ► Artikel lesen | |
| 22.10. | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10. | Valion Bio interim CEO outlines strategic priorities | 2 | Investing.com | ||
| 21.10. | Valion Bio: Interims-CEO Dean Zikria steckt strategische Prioritäten ab | 2 | Investing.com Deutsch | ||
| 21.10. | Valion Bio, Inc.: Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value | 347 | ACCESS Newswire | Interim CEO Dean Zikria's initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company's integrated... ► Artikel lesen | |
| 15.10. | Valion Bio, Inc.: Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone | 372 | ACCESS Newswire | Velocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess... ► Artikel lesen | |
| 14.10. | Valion Bio, Inc.: With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge | 438 | ACCESS Newswire | Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based production... ► Artikel lesen | |
| 14.10. | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.10. | Valion Bio, Inc.: Valion Bio: Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers | 475 | ACCESS Newswire | Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹Medical countermeasures need to scale along... ► Artikel lesen | |
| 05.10. | Valion Bio, Inc.: New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod | 319 | ACCESS Newswire | Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data... ► Artikel lesen | |
| 01.10. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.09. | Valion Bio, Inc.: Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity | 422 | ACCESS Newswire | Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod... ► Artikel lesen | |
| 23.09. | Führungswechsel bei Valion Bio: Dean Zikria wird Interims-CEO | 3 | Investing.com Deutsch | ||
| 23.09. | Valion Bio, Inc.: Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions | 427 | ACCESS Newswire | Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23... ► Artikel lesen | |
| 23.09. | Valion Bio, Inc. - 8-K, Current Report | 7 | SEC Filings |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 51,64 | +5,80 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - JPMorgan hat Fresenius mit einem Kursziel von 55,20 Euro auf "Overweight" belassen. Die Aktie steht zudem auf der "Analyst Focus List" der US-Bank. Die Anlagestory des... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,070 | +5,20 % | ROUNDUP/Aktien Frankfurt Eröffnung: Dax verliert - 26.000-Punkte nun weiter weg | FRANKFURT (dpa-AFX) - Nach dem robusten Wochenstart lässt der Dax am Dienstag unter dem Eindruck der Tech-Schwäche in den USA und einer erneuten militärischen Eskalation im Iran wieder Federn. Im frühen... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,755 | +3,24 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 70,74 | +1,29 % | Guggenheim raises BrightSpring Health stock price target on growth | ||
| CARL ZEISS MEDITEC | 35,760 | +2,17 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| HEARTFLOW | 56,11 | +3,14 % | Heartflow, Inc.: TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients | ||
| ADAPTHEALTH | 7,290 | +16,08 % | AdaptHealth Corp. - 10-Q, Quarterly Report | ||
| PRIVIA HEALTH GROUP | 22,280 | +3,82 % | Privia Health Acquires American Choice Healthcare MSSP Business For $36 Million | ||
| GENEDX | 69,75 | +1,54 % | GeneDx plans to add long-read genome sequencing to portfolio | ||
| BILLIONTOONE | 113,21 | +2,50 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| UNITEDHEALTH | 363,80 | +0,78 % | US-Börse: 46 Aktien schufen $45,5 Billionen | © Foto: Lee Woodgate - Ikon ImagesEine Studie des US-Finanzwissenschaftlers Hendrik Bessembinder kommt zu dem Schluss, dass die Hälfte des in den letzten 100 Jahren an der US-Börse erwirtschafteten... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 14,070 | +5,24 % | LifeStance Health Group Q3 2026 Earnings Preview | ||
| ALIGNMENT HEALTHCARE | 7,720 | +4,47 % | Alignment Healthcare lowers 2026 outlook as it navigates cost headwinds | ||
| OTTOBOCK | 48,500 | +1,57 % | Blue Arbor Technologies Raises $10.5 Million Series A Led by Ottobock | Funds will support completion of feasibility testing, the launch of U.S. clinical studies and product development for the RESTORE Neuromuscular Interface SystemBlue Arbor Technologies, Inc., a company... ► Artikel lesen | |
| GERRESHEIMER | 32,120 | -0,25 % | EQS-News: Gerresheimer AG: Gerresheimer im 3. Quartal 2026 mit Umsatzwachstum und stabilem Adjusted EBITDA | EQS-News: Gerresheimer AG
/ Schlagwort(e): Quartalsergebnis/9-Monatszahlen
Gerresheimer im 3. Quartal 2026 mit Umsatzwachstum und stabilem Adjusted EBITDA
30.10.2026 /... ► Artikel lesen |
VALION BIO INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -4,32 % bei einem Aktienkurs von 0,507 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALION BIO INC finden Sie auf Wallstreet Online.